Theravance Biopharma Stock Price To Sales
| TBPH Stock | USD 9.61 0.36 3.61% |
Theravance Biopharma fundamentals help investors to digest information that contributes to Theravance Biopharma's financial success or failures. It also enables traders to predict the movement of Theravance Stock. The fundamental analysis module provides a way to measure Theravance Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Theravance Biopharma stock.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 10.82 | 10.28 |
Theravance | Price To Sales |
Theravance Biopharma Company Price To Sales Analysis
Theravance Biopharma's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Theravance Biopharma Price To Sales | 7.76 X |
Most of Theravance Biopharma's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Theravance Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Theravance Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Theravance Biopharma is extremely important. It helps to project a fair market value of Theravance Stock properly, considering its historical fundamentals such as Price To Sales. Since Theravance Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Theravance Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Theravance Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Theravance Price To Sales Historical Pattern
Today, most investors in Theravance Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Theravance Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Theravance Biopharma price to sales as a starting point in their analysis.
Theravance Biopharma Price To Sales |
| Timeline |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Theravance Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Theravance Biopharma has a Price To Sales of 7.7584 times. This is 63.75% lower than that of the Pharmaceuticals sector and 92.12% lower than that of the Health Care industry. The price to sales for all United States stocks is 32.06% higher than that of the company.
Theravance Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Theravance Biopharma's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Theravance Biopharma could also be used in its relative valuation, which is a method of valuing Theravance Biopharma by comparing valuation metrics of similar companies.Theravance Biopharma is currently under evaluation in price to sales category among its peers.
Theravance Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Theravance Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Theravance Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
Theravance Fundamentals
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0641 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (0.55) % | ||||
| Current Valuation | 443.89 M | ||||
| Shares Outstanding | 49.17 M | ||||
| Shares Owned By Insiders | 5.92 % | ||||
| Shares Owned By Institutions | 96.75 % | ||||
| Number Of Shares Shorted | 4.92 M | ||||
| Price To Earning | (6.20) X | ||||
| Price To Book | 2.64 X | ||||
| Price To Sales | 7.76 X | ||||
| Revenue | 57.42 M | ||||
| Gross Profit | (12.05 M) | ||||
| EBITDA | (40.87 M) | ||||
| Net Income | (55.19 M) | ||||
| Cash And Equivalents | 132.85 M | ||||
| Cash Per Share | 1.74 X | ||||
| Total Debt | 49.16 M | ||||
| Debt To Equity | 652.20 % | ||||
| Current Ratio | 4.74 X | ||||
| Book Value Per Share | 3.79 X | ||||
| Cash Flow From Operations | (27 M) | ||||
| Short Ratio | 31.50 X | ||||
| Earnings Per Share | (1.03) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 13.2 | ||||
| Number Of Employees | 99 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 490.27 M | ||||
| Total Asset | 382 M | ||||
| Retained Earnings | (909.1 M) | ||||
| Working Capital | 108.77 M | ||||
| Current Asset | 237.47 M | ||||
| Current Liabilities | 49.47 M | ||||
| Net Asset | 382 M |
About Theravance Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Theravance Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theravance Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theravance Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:Check out Theravance Biopharma Piotroski F Score and Theravance Biopharma Altman Z Score analysis. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.03) | Revenue Per Share 1.293 | Quarterly Revenue Growth 0.075 | Return On Assets (0.06) | Return On Equity (0.23) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.